XALKORI 200 mg hard capsules, XALKORI 250 mg hard capsules, Crizotinib 200 mg capsules, Crizotinib 250 mg capsules
A8081075
Approved small_molecule active
Quick answer
XALKORI 200 mg hard capsules, XALKORI 250 mg hard capsules, Crizotinib 200 mg capsules, Crizotinib 250 mg capsules for This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed is a Approved program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed
- Phase
- Approved
- Modality
- small_molecule
- Status
- active